Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Raltegravir may cause hair loss in some patients.

This review covers the potential of repurposing existing drugs for treating COVID-19 and updates on virus- and host-targeting drug candidates, reporting no new experimental results.

This study found that the CYP3A4 rs4646437 genotype was significantly associated with ALT elevation in Japanese patients undergoing asunaprevir plus daclatasvir therapy for chronic HCV infection, suggesting genotyping may help in monitoring patients safely.

This review reports that nirmatrelvir-ritonavir has significant drug-drug interactions with many common dermatological medications, whereas molnupiravir may be an alternative therapy due to the absence of such interactions observed so far.

This case report describes a black HIV-2 patient who experienced reversible nail, hair, and skin hyperpigmentation linked to ritonavir-boosted indinavir therapy, which resolved after discontinuation.

This review examines the main absorption sites and influencing factors for orally administered drugs, highlighting variables such as solubility and gastrointestinal conditions that affect drug absorption in the small intestine and the development of effective drug delivery systems.

In this study, the authors concluded that COVID-19 may not cause direct long-term harm to testicular function, but temporary indirect effects could occur, suggesting a possible delay in pursuing parenthood post-recovery.

This study observed that telogen effluvium, or acute hair loss, often occurs 1 to 3 months after SARS-CoV-2 infection, earlier than classic telogen effluvium.

This study suggests that minoxidil may serve as a suitable reference drug for high permeability classification in the Biopharmaceutics Classification System due to its consistent permeability across different intestinal segments and pH levels.

This review summarizes existing and new cases of generalized pustular psoriasis and acute generalized exanthematous pustulosis associated with COVID-19, noting that over half lacked a known drug trigger.

This report describes six cases of hair loss in African American women after switching to tenofovir alafenamide, suggesting it as a possible adverse effect in this population.

The document concludes that various dermatological treatments and drugs can cause skin reactions and side effects.

This study examined finasteride degradation under stress conditions, identifying three unique degradation products in acidic environments, providing insights into impurity profiling and quality control for finasteride formulations.

This study reported that phytosome formulations of citrus flavonoids naringenin and naringin showed significantly increased oral bioavailability and plasma drug concentration in rabbits, suggesting that phytosome technology effectively addresses the pharmacokinetic limitations of these compounds.

This study reports an increase in the frequency and variety of skin conditions associated with COVID-19, noting that milder cases often present with pernio-like lesions, while severe cases may involve livedo racemosa, retiform purpura, and acral ischemia.

This study used computational methods to identify pranlukast and mirabegron as promising candidates for repurposing against diabetes due to their good binding interactions with the DPP-IV target.

This study demonstrated that a computational screening process can identify existing drugs and natural compounds with potential anti-COVID-19 activity, highlighting some candidates for further experimental validation.

This review discusses drugs and mechanisms possibly responsible for chemical- and drug-induced hair loss but presents no new research findings.

This report describes the first case of hair loss in a patient on ritonavir-boosted atazanavir therapy for HIV, with hair regrowth following a switch to a non-protease inhibitor regimen.

This review highlights that while dexamethasone may reduce mortality in severe COVID-19, no other drugs have proven effectiveness for treatment, emphasizing the need for clinical trials of existing medications.

This letter discusses observations of indinavir's effects on skin, likening them to those of retinoids, but does not present new clinical findings.

This study observed that patients undergoing indinavir/ritonavir therapy for HIV-1 frequently experienced reversible alopecia, likely due to retinoid-like effects, but these were independent of other retinoid-like skin manifestations.

In this study of Egyptian patients on hepatitis C treatment, 34% experienced skin-related side effects from sofosbuvir and daclatasvir, such as itching and hyperpigmentation, but most reactions were mild and reversible without needing to stop therapy.

This study reported that COVID-19 patients treated with nirmatrelvir/ritonavir had lower anti-spike IgG levels and different cytokine patterns compared to those not receiving antiviral treatment, suggesting early antiviral use may alter immune response by reducing viral load and antigen presentation.

This case report presents an HIV-1 patient who experienced osteosclerosis and new bone formation potentially due to long-term indinavir therapy and concurrent use of vitamin A, with symptoms reducing after switching to nelfinavir.

This study found that tenofovir alafenamide fumarate (TAF) is an effective and safer alternative to tenofovir disoproxil fumarate (TDF) for chronic hepatitis B, with fewer long-term side effects like nephrotoxicity and decreased bone density.

This report describes a case of alopecia totalis associated with lopinavir/ritonavir in an HIV-positive patient, which reversed after discontinuation of the drug.

This compilation lists potential side effects, drug interactions, and trade names of various dermatological and antiretroviral medications, but it reports no original research findings.

This review discusses recent advances in monophosphate prodrug strategies for HCV drug discovery, aiming to enhance oral absorption and stability, and reports no new clinical results.

This molecular docking study reported that danoprevir, remdesivir, and saridegib exhibit stronger binding affinities to the main protease of SARS-CoV-2 than the control, suggesting their potential as inhibitors of the virus's replication process.